News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Chari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib

Articles by Chari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib

Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma

ByChari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib,carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma [published online April 4, 2018]. Leuk Lymphoma. 2018:1-7. doi: 10.1080/10428194.2018.1443337.

October 18th 2018

Latest Updated Articles

$Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma$
Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma
Published: October 18th 2018 | Updated:

Trending on AJMC

Government Shutdown Concluded but ACA Subsidies in Limbo

How Trump’s Trade Policy Could Raise Costs, Deepen Drug Shortages

Can a Coffee a Day Keep AFib Away?

Early Measles Vaccination Surges in Texas Infants Amid 2025 Outbreak

How MS Treatment Strategies Are Evolving: Rebecca Spain, MD

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.